Journal
TRANSPLANT INFECTIOUS DISEASE
Volume 13, Issue 3, Pages 324-328Publisher
WILEY
DOI: 10.1111/j.1399-3062.2010.00575.x
Keywords
human metapneumovirus; immunosuppression; hematopoietic stem cell transplant; lung transplant; ribavirin; cellular rejection
Categories
Funding
- NHLBI NIH HHS [T32 HL091816, T32 HL091816-03] Funding Source: Medline
Ask authors/readers for more resources
Human metapneumovirus (hMPV) is an emerging human pulmonary pathogen that is genetically related to respiratory syncytial virus. It has been increasingly associated with respiratory illnesses over the last few decades. Immunocompromised patients are particularly susceptible with resultant morbidity and mortality. We describe our experience with 9 immunocompromised patients diagnosed with pneumonia secondary to hMPV, 2 of whom were successfully treated with aerosolized and oral ribavirin along with intravenous immunoglobulin (IVIG). We suggest that hMPV should be considered in the differential diagnosis of immunocompromised patients with acute respiratory illness. Ribavirin (oral and aerosolized) with IVIG is potentially an effective treatment option for those with severe disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available